Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: A case report

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Uemura, Marc ^a   Trinh, Van A ^a   Haymaker, Cara ^a   Jackson, Natalie ^a   Kim, Dae Won ^a   Allison, James P ^a   Sharma, Padmanee ^a   Vence, Luis ^a   Bernatchez, Chantale ^a   Hwu, Patrick ^a   Diab, Adi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Checkpoint inhibitors; Crohn's disease; CTLA 4; Metastatic melanoma; PD 1; Pembrolizumab; Tocilizumab

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; B RAF KINASE; INTERLEUKIN 17; INTERLEUKIN 6; MERCAPTOPURINE; PEMBROLIZUMAB; PREDNISONE; TOCILIZUMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL ABSCESS; ABDOMINAL DRAINAGE; ADULT; ARTICLE; BRAF GENE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROHN DISEASE; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EFFECTOR CELL; FEMALE; GENE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MEDICAL HISTORY; METASTATIC MELANOMA; MIDDLE AGED; ONCOGENE C KIT; ONCOGENE N RAS; RADIOSURGERY; SENTINEL LYMPH NODE BIOPSY; SKIN NODULE; TH17 CELL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNITY; COMPLICATION; DRUG EFFECTS; MELANOMA; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNITY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-6; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84984920567     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0309-7     Document Type: Article

References (15)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-82.
2. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234-40.
3. Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014;35(10):493-500.
4. Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011;29(15):2505.
5. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.
6. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-5.
7. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18.
8. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-95.
9. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126(4):989-96. discussion 947.
10. Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169-78.
11. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-65.
12. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64.
13. Ramesh R, Kozhaya L, McKevitt K, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211(1):89-104.
14. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014;371(4):326-38.
15. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-56.